Eli Lilly Management
Management criteria checks 2/4
Eli Lilly's CEO is Dave Ricks, appointed in Jan 2017, has a tenure of 7.92 years. total yearly compensation is $26.57M, comprised of 6.1% salary and 93.9% bonuses, including company stock and options. directly owns 0.067% of the company’s shares, worth $464.63M. The average tenure of the management team and the board of directors is 6.3 years and 8.5 years respectively.
Key information
Dave Ricks
Chief executive officer
US$26.6m
Total compensation
| CEO salary percentage | 6.1% |
| CEO tenure | 7.9yrs |
| CEO ownership | 0.07% |
| Management average tenure | 6.3yrs |
| Board average tenure | 8.5yrs |
Recent management updates
Recent updates
Eli Lilly: A Rare Buying Opportunity
Dec 17Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.50
Dec 14
Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
Dec 04Here's Why Eli Lilly (NYSE:LLY) Can Manage Its Debt Responsibly
Nov 29Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
Nov 28Eli Lilly Stock: Unexpected Developments (Rating Downgrade)
Nov 21Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next
Nov 01Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges
Oct 30Eli Lilly Buy On Weakness Signal (Technical Analysis)
Oct 20Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
Sep 30Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Sep 20Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth
Sep 18Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside
Sep 04Eli Lilly: Tirzepatide's Winning Streak Continues
Aug 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$8b |
| Jun 30 2024 | n/a | n/a | US$7b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$27m | US$2m | US$5b |
| Sep 30 2023 | n/a | n/a | US$5b |
| Jun 30 2023 | n/a | n/a | US$6b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$21m | US$2m | US$6b |
| Sep 30 2022 | n/a | n/a | US$6b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$22m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$6b |
| Dec 31 2020 | US$24m | US$1m | US$6b |
| Sep 30 2020 | n/a | n/a | US$6b |
| Jun 30 2020 | n/a | n/a | US$6b |
| Mar 31 2020 | n/a | n/a | US$6b |
| Dec 31 2019 | US$21m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$4b |
| Jun 30 2019 | n/a | n/a | US$4b |
| Mar 31 2019 | n/a | n/a | US$3b |
| Dec 31 2018 | US$17m | US$1m | US$3b |
| Sep 30 2018 | n/a | n/a | US$372m |
| Jun 30 2018 | n/a | n/a | -US$166m |
| Mar 31 2018 | n/a | n/a | US$1b |
| Dec 31 2017 | US$16m | US$1m | -US$86m |
Compensation vs Market: Dave's total compensation ($USD26.57M) is above average for companies of similar size in the US market ($USD12.85M).
Compensation vs Earnings: Dave's compensation has increased by more than 20% in the past year.
CEO
Dave Ricks (56 yo)
7.9yrs
Tenure
US$26,565,732
Compensation
Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 7.9yrs | US$26.57m | 0.067% $ 464.6m | |
| EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology | 6.5yrs | US$11.85m | 0.021% $ 148.6m | |
| Executive VP | 4.8yrs | US$7.01m | 0.0034% $ 23.4m | |
| Executive VP & President of Loxo | no data | US$4.89m | 0.0023% $ 15.8m | |
| Executive VP & CFO | less than a year | no data | 0.0012% $ 8.5m | |
| Senior VP of Finance & Chief Accounting Officer | 12.1yrs | no data | 0.00080% $ 5.5m | |
| EVP & Chief Information and Digital Officer | 3.6yrs | US$5.10m | 0.0012% $ 8.5m | |
| EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer | 3.5yrs | no data | 0.00088% $ 6.1m | |
| Executive Vice President of Human Resources & Diversity | 2yrs | no data | 0.00093% $ 6.4m | |
| Senior VP & President of Elanco Animal Health | 16.9yrs | US$5.38m | no data | |
| SVP of Global Active Pharmaceutical Ingredient | 8.3yrs | no data | no data | |
| EVP & President of Lilly Neuroscience | 6.3yrs | no data | 0.0073% $ 50.3m |
6.3yrs
Average Tenure
54yo
Average Age
Experienced Management: LLY's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 7.9yrs | US$26.57m | 0.067% $ 464.6m | |
| Independent Director | 3.9yrs | US$335.50k | no data | |
| Chairman Emeritus | 15.9yrs | US$13.06m | no data | |
| Independent Director | 19.1yrs | US$344.88k | 0.000010% $ 69.1k | |
| Independent Director | 15.7yrs | US$336.00k | 0.000080% $ 553.1k | |
| Independent Director | 12.5yrs | US$349.15k | no data | |
| Independent Director | 2.6yrs | US$319.00k | 0.000040% $ 276.5k | |
| Lead Independent Director | 8.8yrs | US$373.00k | no data | |
| Independent Director | 13yrs | US$336.00k | no data | |
| Independent Director | 8.2yrs | US$345.00k | no data | |
| Independent Director | 6yrs | US$359.00k | no data | |
| Independent Director | 3.8yrs | US$316.00k | no data |
8.5yrs
Average Tenure
62.5yo
Average Age
Experienced Board: LLY's board of directors are considered experienced (8.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:15 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eli Lilly and Company is covered by 63 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Alistair Campbell | Berenberg |